P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome
Acute coronary syndrome (ACS) is a continuum of disease that includes non–ST-segment elevation ACS and ST-segment elevation myocardial infarction. The purpose of this article is to define the developing role of ticagrelor in ACS and compare it to currently available P2Y12 receptor inhibitors. While...
Gespeichert in:
| Veröffentlicht in: | The Annals of pharmacotherapy 2011-09, Vol.45 (9), p.1151-1156 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1156 |
|---|---|
| container_issue | 9 |
| container_start_page | 1151 |
| container_title | The Annals of pharmacotherapy |
| container_volume | 45 |
| creator | Crouch, Michael A Colucci, Vince J Howard, Patricia A Spinier, Sarah A |
| description | Acute coronary syndrome (ACS) is a continuum of disease that includes non–ST-segment elevation ACS and ST-segment elevation myocardial infarction. The purpose of this article is to define the developing role of ticagrelor in ACS and compare it to currently available P2Y12 receptor inhibitors. While Clopidogrel remains the “workhorse” P2Y12 receptor inhibitor for many patients with ACS and prasugrel has an established role in select situations, clinicians must now assimilate the evolving role of ticagrelor. Although ticagrelor offers important advances in the management of ACS (eg, reversibility), there are also notable clinical considerations (eg, unique adverse effects such as dyspnea). Based on the current evidence, we propose an algorithm to aid clinicians in the selection of a P2Y12 receptor inhibitor for patients with ACS in various clinical situations. |
| doi_str_mv | 10.1345/aph.1Q141 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_887507400</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1Q141</sage_id><sourcerecordid>887507400</sourcerecordid><originalsourceid>FETCH-LOGICAL-p156t-9c6da3ee7e01b5f4871ab49a12c0a4d4d6bdc670646daf66030462a519f9fb2e3</originalsourceid><addsrcrecordid>eNo1kLlOxDAURS0EYi_4AeQKqgzPju0kdKMRmzSIvaAyTvKSCZrYwXEK_h6zVe8WR1f3HUKOGMxYKuSZGVYz9sAE2yC7TAqeKJ7BZsygIAGeww7ZG8d3ACgYL7bJDme55LIodsnbPX9lnD5ihUNwnt7YVVd2MY3nMQdsvQmdbelzV5nW4zoinQ2OhhXSW2NNiz3aQF1D59UUkC6cd9b4T_r0aWvvejwgW41Zj3j4d_fJy-XF8-I6Wd5d3Szmy2RgUoWkqFRtUsQMgZWyEXnGTCkKw3gFRtSiVmVdqQyUiFyjFKQgFDeSFU3RlBzTfXL62zt49zHhGHTfjRWu18aim0ad55mETABE8viPnMoeaz34ro-L9b-UCJz8AmN8T7-7ydu4XDPQ37Z1tK1_bKdfvGVvlg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>887507400</pqid></control><display><type>article</type><title>P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Crouch, Michael A ; Colucci, Vince J ; Howard, Patricia A ; Spinier, Sarah A</creator><creatorcontrib>Crouch, Michael A ; Colucci, Vince J ; Howard, Patricia A ; Spinier, Sarah A</creatorcontrib><description>Acute coronary syndrome (ACS) is a continuum of disease that includes non–ST-segment elevation ACS and ST-segment elevation myocardial infarction. The purpose of this article is to define the developing role of ticagrelor in ACS and compare it to currently available P2Y12 receptor inhibitors. While Clopidogrel remains the “workhorse” P2Y12 receptor inhibitor for many patients with ACS and prasugrel has an established role in select situations, clinicians must now assimilate the evolving role of ticagrelor. Although ticagrelor offers important advances in the management of ACS (eg, reversibility), there are also notable clinical considerations (eg, unique adverse effects such as dyspnea). Based on the current evidence, we propose an algorithm to aid clinicians in the selection of a P2Y12 receptor inhibitor for patients with ACS in various clinical situations.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1Q141</identifier><identifier>PMID: 21852599</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Acute Coronary Syndrome - drug therapy ; Acute Coronary Syndrome - physiopathology ; Adenosine - adverse effects ; Adenosine - analogs & derivatives ; Adenosine - pharmacology ; Adenosine - therapeutic use ; Algorithms ; Dyspnea - chemically induced ; Humans ; Purinergic P2Y Receptor Antagonists - adverse effects ; Purinergic P2Y Receptor Antagonists - pharmacology ; Purinergic P2Y Receptor Antagonists - therapeutic use ; Receptors, Purinergic P2Y12 - drug effects ; Receptors, Purinergic P2Y12 - metabolism</subject><ispartof>The Annals of pharmacotherapy, 2011-09, Vol.45 (9), p.1151-1156</ispartof><rights>2011 Harvey Whitney Books Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1345/aph.1Q141$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1345/aph.1Q141$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21818,27923,27924,43620,43621</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21852599$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crouch, Michael A</creatorcontrib><creatorcontrib>Colucci, Vince J</creatorcontrib><creatorcontrib>Howard, Patricia A</creatorcontrib><creatorcontrib>Spinier, Sarah A</creatorcontrib><title>P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>Acute coronary syndrome (ACS) is a continuum of disease that includes non–ST-segment elevation ACS and ST-segment elevation myocardial infarction. The purpose of this article is to define the developing role of ticagrelor in ACS and compare it to currently available P2Y12 receptor inhibitors. While Clopidogrel remains the “workhorse” P2Y12 receptor inhibitor for many patients with ACS and prasugrel has an established role in select situations, clinicians must now assimilate the evolving role of ticagrelor. Although ticagrelor offers important advances in the management of ACS (eg, reversibility), there are also notable clinical considerations (eg, unique adverse effects such as dyspnea). Based on the current evidence, we propose an algorithm to aid clinicians in the selection of a P2Y12 receptor inhibitor for patients with ACS in various clinical situations.</description><subject>Acute Coronary Syndrome - drug therapy</subject><subject>Acute Coronary Syndrome - physiopathology</subject><subject>Adenosine - adverse effects</subject><subject>Adenosine - analogs & derivatives</subject><subject>Adenosine - pharmacology</subject><subject>Adenosine - therapeutic use</subject><subject>Algorithms</subject><subject>Dyspnea - chemically induced</subject><subject>Humans</subject><subject>Purinergic P2Y Receptor Antagonists - adverse effects</subject><subject>Purinergic P2Y Receptor Antagonists - pharmacology</subject><subject>Purinergic P2Y Receptor Antagonists - therapeutic use</subject><subject>Receptors, Purinergic P2Y12 - drug effects</subject><subject>Receptors, Purinergic P2Y12 - metabolism</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kLlOxDAURS0EYi_4AeQKqgzPju0kdKMRmzSIvaAyTvKSCZrYwXEK_h6zVe8WR1f3HUKOGMxYKuSZGVYz9sAE2yC7TAqeKJ7BZsygIAGeww7ZG8d3ACgYL7bJDme55LIodsnbPX9lnD5ihUNwnt7YVVd2MY3nMQdsvQmdbelzV5nW4zoinQ2OhhXSW2NNiz3aQF1D59UUkC6cd9b4T_r0aWvvejwgW41Zj3j4d_fJy-XF8-I6Wd5d3Szmy2RgUoWkqFRtUsQMgZWyEXnGTCkKw3gFRtSiVmVdqQyUiFyjFKQgFDeSFU3RlBzTfXL62zt49zHhGHTfjRWu18aim0ad55mETABE8viPnMoeaz34ro-L9b-UCJz8AmN8T7-7ydu4XDPQ37Z1tK1_bKdfvGVvlg</recordid><startdate>201109</startdate><enddate>201109</enddate><creator>Crouch, Michael A</creator><creator>Colucci, Vince J</creator><creator>Howard, Patricia A</creator><creator>Spinier, Sarah A</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201109</creationdate><title>P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome</title><author>Crouch, Michael A ; Colucci, Vince J ; Howard, Patricia A ; Spinier, Sarah A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p156t-9c6da3ee7e01b5f4871ab49a12c0a4d4d6bdc670646daf66030462a519f9fb2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Acute Coronary Syndrome - drug therapy</topic><topic>Acute Coronary Syndrome - physiopathology</topic><topic>Adenosine - adverse effects</topic><topic>Adenosine - analogs & derivatives</topic><topic>Adenosine - pharmacology</topic><topic>Adenosine - therapeutic use</topic><topic>Algorithms</topic><topic>Dyspnea - chemically induced</topic><topic>Humans</topic><topic>Purinergic P2Y Receptor Antagonists - adverse effects</topic><topic>Purinergic P2Y Receptor Antagonists - pharmacology</topic><topic>Purinergic P2Y Receptor Antagonists - therapeutic use</topic><topic>Receptors, Purinergic P2Y12 - drug effects</topic><topic>Receptors, Purinergic P2Y12 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crouch, Michael A</creatorcontrib><creatorcontrib>Colucci, Vince J</creatorcontrib><creatorcontrib>Howard, Patricia A</creatorcontrib><creatorcontrib>Spinier, Sarah A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crouch, Michael A</au><au>Colucci, Vince J</au><au>Howard, Patricia A</au><au>Spinier, Sarah A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2011-09</date><risdate>2011</risdate><volume>45</volume><issue>9</issue><spage>1151</spage><epage>1156</epage><pages>1151-1156</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><abstract>Acute coronary syndrome (ACS) is a continuum of disease that includes non–ST-segment elevation ACS and ST-segment elevation myocardial infarction. The purpose of this article is to define the developing role of ticagrelor in ACS and compare it to currently available P2Y12 receptor inhibitors. While Clopidogrel remains the “workhorse” P2Y12 receptor inhibitor for many patients with ACS and prasugrel has an established role in select situations, clinicians must now assimilate the evolving role of ticagrelor. Although ticagrelor offers important advances in the management of ACS (eg, reversibility), there are also notable clinical considerations (eg, unique adverse effects such as dyspnea). Based on the current evidence, we propose an algorithm to aid clinicians in the selection of a P2Y12 receptor inhibitor for patients with ACS in various clinical situations.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>21852599</pmid><doi>10.1345/aph.1Q141</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1060-0280 |
| ispartof | The Annals of pharmacotherapy, 2011-09, Vol.45 (9), p.1151-1156 |
| issn | 1060-0280 1542-6270 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_887507400 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Acute Coronary Syndrome - drug therapy Acute Coronary Syndrome - physiopathology Adenosine - adverse effects Adenosine - analogs & derivatives Adenosine - pharmacology Adenosine - therapeutic use Algorithms Dyspnea - chemically induced Humans Purinergic P2Y Receptor Antagonists - adverse effects Purinergic P2Y Receptor Antagonists - pharmacology Purinergic P2Y Receptor Antagonists - therapeutic use Receptors, Purinergic P2Y12 - drug effects Receptors, Purinergic P2Y12 - metabolism |
| title | P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T23%3A47%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P2Y12%20Receptor%20Inhibitors:%20Integrating%20Ticagrelor%20into%20the%20Management%20of%20Acute%20Coronary%20Syndrome&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Crouch,%20Michael%20A&rft.date=2011-09&rft.volume=45&rft.issue=9&rft.spage=1151&rft.epage=1156&rft.pages=1151-1156&rft.issn=1060-0280&rft.eissn=1542-6270&rft_id=info:doi/10.1345/aph.1Q141&rft_dat=%3Cproquest_pubme%3E887507400%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=887507400&rft_id=info:pmid/21852599&rft_sage_id=10.1345_aph.1Q141&rfr_iscdi=true |